Cell And Gene Therapy Field Sees Opportunity Under Trump

The cell and gene therapy field has reached an inflection point in the US as the second Trump Administration begins and advocates argue the sector could fit well with the “MAHA” agenda.

Cell and gene therapies are at a breakout point, said Alliance for Regenerative Medicine CEO Tim Hunt. (Shutterstock)

Cell and gene therapy advocates believe they can make the case that the products are a good fit with the incoming Trump Administration’s health care vision.

More from Cell & Gene Therapies

More from Legislation